Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Thomas Burns, Chairman and chief executive officer of Glaukos

“The addition of RO-104 and exclusive access to the proprietary RevMod platform in the field of retina represents an important strategic step in the continued expansion of our retinal franchise and is highly complementary to our ongoing retinal R&D initiatives.”

Thomas Burns, Chairman and chief executive officer of Glaukos

“This licensing agreement adds a first-in-class, tri-specific biologic to strengthen our retina pipeline and provides a differentiated discovery engine with the potential to generate several additional retinal therapeutic candidates across a variety of retinal diseases.”

Thomas Burns, Chairman and chief executive officer of Glaukos

“We believe the unique ability of RO-104 to simultaneously target VEGF-A, VEGF-C, and Ang-2 could offer meaningful advantages in the treatment of retinal vascular disease while further expanding our long-term innovation capabilities in retina.”

Ramanath Bhandari, Chairman and chief executive officer of RevOpsis

“This license agreement represents an important validation of our proprietary RevMod platform and our strategy of developing next-generation multi-specific therapeutics for retinal diseases.”

Ramanath Bhandari, Chairman and chief executive officer of RevOpsis

“Glaukos brings deep ophthalmology expertise and a strong track record of developing and commercializing innovative therapies.”

Ramanath Bhandari, Chairman and chief executive officer of RevOpsis

“We believe this partnership provides an excellent opportunity to help advance our lead asset while expanding our platform into a broader portfolio of potentially transformative retinal treatments.”